Cargando…

Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E

The IMV envelope protein D8 is an adhesion molecule and a major immunodominant antigen of vaccinia virus (VACV). Here we identified the optimal D8 ligand to be chondroitin sulfate E (CS-E). CS-E is characterized by a disaccharide moiety with two sulfated hydroxyl groups at positions 4′ and 6′ of Gal...

Descripción completa

Detalles Bibliográficos
Autores principales: Matho, Michael H., de Val, Natalia, Miller, Gregory M., Brown, Joshua, Schlossman, Andrew, Meng, Xiangzhi, Crotty, Shane, Peters, Bjoern, Xiang, Yan, Hsieh-Wilson, Linda C., Ward, Andrew B., Zajonc, Dirk M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256255/
https://www.ncbi.nlm.nih.gov/pubmed/25474621
http://dx.doi.org/10.1371/journal.ppat.1004495
_version_ 1782347555156262912
author Matho, Michael H.
de Val, Natalia
Miller, Gregory M.
Brown, Joshua
Schlossman, Andrew
Meng, Xiangzhi
Crotty, Shane
Peters, Bjoern
Xiang, Yan
Hsieh-Wilson, Linda C.
Ward, Andrew B.
Zajonc, Dirk M.
author_facet Matho, Michael H.
de Val, Natalia
Miller, Gregory M.
Brown, Joshua
Schlossman, Andrew
Meng, Xiangzhi
Crotty, Shane
Peters, Bjoern
Xiang, Yan
Hsieh-Wilson, Linda C.
Ward, Andrew B.
Zajonc, Dirk M.
author_sort Matho, Michael H.
collection PubMed
description The IMV envelope protein D8 is an adhesion molecule and a major immunodominant antigen of vaccinia virus (VACV). Here we identified the optimal D8 ligand to be chondroitin sulfate E (CS-E). CS-E is characterized by a disaccharide moiety with two sulfated hydroxyl groups at positions 4′ and 6′ of GalNAc. To study the role of antibodies in preventing D8 adhesion to CS-E, we have used a panel of murine monoclonal antibodies, and tested their ability to compete with CS-E for D8 binding. Among four antibody specificity groups, MAbs of one group (group IV) fully abrogated CS-E binding, while MAbs of a second group (group III) displayed widely varying levels of CS-E blocking. Using EM, we identified the binding site for each antibody specificity group on D8. Recombinant D8 forms a hexameric arrangement, mediated by self-association of a small C-terminal domain of D8. We propose a model in which D8 oligomerization on the IMV would allow VACV to adhere to heterogeneous population of CS, including CS-C and potentially CS-A, while overall increasing binding efficiency to CS-E.
format Online
Article
Text
id pubmed-4256255
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42562552014-12-11 Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E Matho, Michael H. de Val, Natalia Miller, Gregory M. Brown, Joshua Schlossman, Andrew Meng, Xiangzhi Crotty, Shane Peters, Bjoern Xiang, Yan Hsieh-Wilson, Linda C. Ward, Andrew B. Zajonc, Dirk M. PLoS Pathog Research Article The IMV envelope protein D8 is an adhesion molecule and a major immunodominant antigen of vaccinia virus (VACV). Here we identified the optimal D8 ligand to be chondroitin sulfate E (CS-E). CS-E is characterized by a disaccharide moiety with two sulfated hydroxyl groups at positions 4′ and 6′ of GalNAc. To study the role of antibodies in preventing D8 adhesion to CS-E, we have used a panel of murine monoclonal antibodies, and tested their ability to compete with CS-E for D8 binding. Among four antibody specificity groups, MAbs of one group (group IV) fully abrogated CS-E binding, while MAbs of a second group (group III) displayed widely varying levels of CS-E blocking. Using EM, we identified the binding site for each antibody specificity group on D8. Recombinant D8 forms a hexameric arrangement, mediated by self-association of a small C-terminal domain of D8. We propose a model in which D8 oligomerization on the IMV would allow VACV to adhere to heterogeneous population of CS, including CS-C and potentially CS-A, while overall increasing binding efficiency to CS-E. Public Library of Science 2014-12-04 /pmc/articles/PMC4256255/ /pubmed/25474621 http://dx.doi.org/10.1371/journal.ppat.1004495 Text en © 2014 Matho et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Matho, Michael H.
de Val, Natalia
Miller, Gregory M.
Brown, Joshua
Schlossman, Andrew
Meng, Xiangzhi
Crotty, Shane
Peters, Bjoern
Xiang, Yan
Hsieh-Wilson, Linda C.
Ward, Andrew B.
Zajonc, Dirk M.
Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title_full Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title_fullStr Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title_full_unstemmed Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title_short Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E
title_sort murine anti-vaccinia virus d8 antibodies target different epitopes and differ in their ability to block d8 binding to cs-e
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256255/
https://www.ncbi.nlm.nih.gov/pubmed/25474621
http://dx.doi.org/10.1371/journal.ppat.1004495
work_keys_str_mv AT mathomichaelh murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT devalnatalia murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT millergregorym murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT brownjoshua murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT schlossmanandrew murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT mengxiangzhi murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT crottyshane murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT petersbjoern murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT xiangyan murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT hsiehwilsonlindac murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT wardandrewb murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse
AT zajoncdirkm murineantivacciniavirusd8antibodiestargetdifferentepitopesanddifferintheirabilitytoblockd8bindingtocse